Amgen (NASDAQ:AMGN) recently reported second-quarter results that blew past consensus estimates on the top and bottom lines. The company's mature product line is still losing ground thanks to losses of exclusivity, but that didn't stop recent share buybacks from raising earnings by a few percentage points.

Amgen results: The raw numbers

Metric Q2 2019 Q2 2018 Change
Revenue $5.87 billion $6.06 billion (3%)
Income from operations $2.68 billion $2.83 billion (5%)
Earnings per share $3.57 $3.48 3%

Data source: Amgen Inc.

What happened with Amgen this quarter?

If there were awards for growing your bottom line after your best-selling brands lose exclusivity, Amgen's trophy case would be full of them. Sliding sales of Neulasta, Neupogen, and Sensipar pulled total revenue down by a combined $601 million, but the company still raised earnings per share by repurchasing heaps of those shares over the past year.

Amgen didn't report any huge gains from any single brand. Instead, there was encouraging growth from around a dozen drugs with a lot more patent-protected market exclusivity, including Enbrel. The anti-inflammation treatment launched decades ago, but second-quarter sales still grew 5% to $1.36 billion.

Enbrel sales rose thanks to a higher net price, while sales of all of the following products experienced increased demand:

  • Sales of denosumab, a bone density builder that Amgen markets as Prolia and Xgeva, rose 13% to a combined $1.2 billion.
  • Year-over-year sales of Amgen's cholesterol-lowering injection Repatha and multiple myeloma treatment Kyprolis grew by low-single-digit percentages, to $152 million and $267 million, respectively.
  • Amgen's first bi-specific T cell engager, Blincyto, is still climbing since it earned approval last year to treat leukemia patients already in remission for their first or second time. Blincyto sales rose to $78 million, which was 13% more than during the previous-year period.
  • The company's hyperparathyroidism treatment Parsabiv got off to a slow start in 2017, but it's finally taking off. Parsabiv sales came in 130% higher than the previous-year period, reaching $168 million.
  • The company didn't launch the first-in-class migraine-preventing drug, Aimovig, until the middle of 2018. Compared to the first quarter of 2019, though, sales of the monthly injection grew 41% to $83 million.
Lab employees in full clean-room gear looking through microscopes.

Image source: Getty Images.

What management had to say

Robert A. Bradway, Amgen's CEO, was pleased to report increasing demand for drugs on the market and candidates in development: "With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders."

The most exciting first-in-class drug in Amgen's pipeline is AMG 510, an oral cancer treatment that inhibits out-of-control KRAS proteins so they can't accelerate an array of different malignancies. The company has a registrational study slated for later this year, and investors want to keep an eye on a potential contender that Mirati Therapeutics is testing in a human proof-of-concept study.

Looking forward

Amgen didn't change the high side of any forward expectations, but management did raise the lower ends of guided ranges provided three months ago. Total revenue is expected to fall in a range between $22.4 billion and $22.9 billion, and adjusted earnings are headed for a range between $13.75 per share and $14.30 per share.

Sliding sales of Neulasta and others have crimped profit growth, but Amgen's operations still generated an impressive $9.7 billion in free cash flow over the past 12 months. Amgen only needs 36% of trailing free cash flow to make payments on a dividend that currently offers a 3.2% yield.

The company has raised its payout a stunning 418% over the past decade. If Aimovig and Parsabiv and AMG 510 continue exceeding expectations, the next 10 years could work out even better for shareholders.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.